Eli Lilly Announces Positive Phase 2 Results for Retatrutide in Obesity Treatment, Demonstrating 24.2% Weight Loss at 48 Weeks

Recently, Eli Lilly and Company announced the latest Phase 2 study data for retatrutide in the treatment of obesity.

According to the data, at 24 weeks, retatrutide (1mg, 4mg, 8mg, or 12mg) achieved the primary endpoint using efficacy estimation goals in non-diabetic subjects who were obese or overweight, with an average weight loss of 17.5% (18.7 kg). For the secondary endpoint, retatrutide resulted in an average weight loss of 24.2% (26.2 kg) at the end of 48 weeks of treatment. These findings were presented at the 83rd Scientific Sessions of the American Diabetes Association (ADA) and simultaneously published in The New England Journal of Medicine (NEJM).

Editor: Mu Mian

Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.